Investigation of microglial involvement in the effects of intranasal oxytocin on social behavior: a placebo-controlled, double-blind, crossover trial in healthy subjects.

未提供0 个研究点目标入组 24 人开始时间: 2024年7月17日最近更新: 2025年5月19日

试验速览

暂无简介。

•(1) Males between the ages of 18 and 55 at the time consent is obtained
•(2) Total intelligence quotient > 80
•(3) Individuals who have given their written consent to participate in this study

•(1) Has been diagnosed with a mental illness
•(2) Use of psychotropic drugs in the past 6 months
•(3) History of hypersensitivity to oxytocin
•(4) History of epileptic seizures or head trauma with loss of consciousness for more than 5 minutes
•(5) History of alcohol-related or other substance-related disorders
•(6) Taking anti-inflammatory medications, which cannot be discontinued from one month prior to study drug administration (Visit 1) until Visit 2 or the end of the study
•(7) Has a family history of male breast cancer
•(8) Patients with a serious medical condition
•(9) Have a drug allergy, food allergy, or a specific constitution
•(10) Who cannot give consent to use contraception during the study period
•(11) Participate in any other research or clinical research (except for research involving PET imaging using [11C]DPA713) and receive any medication within 120 days prior to obtaining consent
•(12) Other subjects deemed ineligible for this study by the Principal Investigator(s).

PET measurement: Binding potential (BP)ND of [11C]DPA713

发起方

未提供